ICP Reports

Cancer research spans all disciplines of science, from the social and humanistic to fundamental biomedicine. Cancer research in wealthy countries dominates disease-specific biomedical research. However, most research funding is skewed towards fundamental biology and treatment, particularly cancer medicines. While this…

Over the last decade the ICP has published over 100 peer reviewed reports covering all areas of cancer public policy, from a critical analysis of the future of cancer drug development to global commissions on childhood cancers, surgery and affordable…

By the year 2030, the number of new cancer cases worldwide is projected to rise to 21.3 million an- nually, up from the estimated 12.7 mil- lion cancer cases currently diagnosed. Of the 21.3 million new cases every year, approximately…

The media plays a vital role in informing the public about new developments in cancer research and influencing cancer policy. This is no easy task, in view of the myriad of trials and wonder drugs that purport to be the…

Since the 2011 UN High Level Summit on non-communicable diseases, cancer has been increasingly recognised as a major global health issue by the broader international health community. With a smattering of partners the Union for International Cancer Control has now…

Sub replacement fertility levels have persisted across Europe since the 1980s. This has resulted in a demographic transformation within Europe characterised by population ageing, a decline in population growth, and a subsequent rise in old age dependency ratios. European governments…

On June 1, 2014, the penultimate day of the 50th Annual Meeting of the American Society of Clini- cal Oncology (ASCO), the discussion on value in cancer care was rekindled, but this time on a global scale. The session, “ASCO/European…

Cancer can have profound social and economic consequences for people in India, often leading to family impoverishment and societal inequity. Reported age-adjusted incidence rates for cancer are still quite low in the demographically young country. Slightly more than 1 million…

Cancer is one of the major non-communicable diseases posing a threat to world health. Unfortunately, improvements in socioeconomic conditions are usually associated with increased cancer incidence. In this Commission, we focus on China, India, and Russia, which share rapidly rising…

Jap J Clin Onc 2013, 43(12): 1159-1169

Evidence-informed frameworks for cost-effective cancer prevention and management are essential for delivering equitable outcomes and tackling the growing burden of cancer in all resource settings. Evidence can help address the demand side pressures (ie, pressures exerted by people who need…

Fernandez-Luengo R, Leal J, Gray A, and Sullivan R.

Lancet Oncology 2013, 14(12): 1165-1174.

Annals Oncol 2013, 24(11): 2897-2902.

The Institute of Cancer Policy is proud to have collaborated with one of the worlds leading global health institutions, International Prevention Research Institute and major worldwide contributors to produce the first major State of Oncology 2013 book:

Translational research is a complex cumulative process that takes time. However, the operating environment for cancer centers engaged in translational research is now financially insecure. Centers are challenged to improve results and reduce time from discovery to practice innovations. Performance…

The diagnosis and treatment of cancer have a significant impact on mental health, and are associated with a physical, emotional and financial burden both on individuals and on society as a whole. Both these major non-communicable diseases have close interdependencies.…

Non-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health ministries and health-care systems…

Childhood cancer is a major global health issue. Every year, almost 100 000 children die from cancer before the age of 15 years, more than 90% of them in resource-limited countries. Here, we review the key policy issues for the…

The world faces an unprecedented growth in cancer incidence over the next fifty years, the majority of the burden falling on low-middle income countries. At the same time as the changing demographic profiles, including global population ageing we are also…

Surgery is the main modality of control and cure for solid cancer in developed as well as low-middle income countries (LMIC) and is the only modality in a large proportion of cases globally. Research and development in surgical oncology are…

Great strides have been made over recent decades in the treatment of cancer. Outcomes are improving and the numbers of cancer survivors are rising rapidly. These advances have taken place on the back of remarkable research, which has fostered a…

Overcoming childhood cancers is critically dependent on the state of research. Understanding how, with whom and what the research community is doing with childhood cancers is essential for ensuring the evidence-based policies at national and European level to sup- port…

With global spend on cancer research from the public sector now in excess of 14 billion euro, as well as the increasing burden of disease in market economies and low-middle income countries through changing demographics (ageing and population growth) cancer…

The US model of Cancer Centres created by the National Cancer Act in 1971 has been one of the most tried and tested models of organised disease-specific scientific endeavors in the world. With many countries, particularly those in Europe now…